medigraphic.com
Instituto Nacional de Salud Pública

2018, Número 6

<< Anterior Siguiente >>

salud publica mex 2018; 60 (6)


Prevalencia e incidencia de infección por virus de papiloma humano en canal anal en hombres mexicanos: Necesidad de políticas de prevención universal

Posso H, León-Maldonado L, Allen-Leigh B, Salmerón J, Quiterio M, Giuliano AR, Sudenga SL, Nyitray AG, Torres BN, Abrahamsen M, Lazcano-Ponce E

Idioma: Ingles.
Referencias bibliográficas: 31
Paginas: 645-652
Archivo PDF: 360.16 Kb.


RESUMEN

Objetivo. Generar evidencia que apoye la vacunación universal contra VPH. Material y métodos. Estudio prospectivo con hombres 18-70 años (n=665) de Cuernavaca, México con cuestionarios y genotipificación de VPH en muestras (2+mediciones). Se estimó prevalencia e incidencia; se calcularon tasas de prevalencia con regresión Poisson. Se estimó persona-tiempo para infecciones incidentes. Resultados. Prevalencia de infección anal: cualquier tipo de VPH=15%, altoriesgo= 8.4%, VPH16=1.4%, tipos en vacuna tetravalente=4.4% y tipos en vacuna nonavalente=6.3%. Factores asociados con infección prevalente: 50+ parejas sexuales femeninas en la vida (tasa de prevalencia ajustada, TPa=3.25, IC95%:1.12-9.47); 10+ parejas sexuales masculinas en la vida (TPa=3.06, IC95%:1.4- 6.68) y 1+ parejas masculinas (sexo anal) recientes (TPa=2.28, IC95%:1.15-4.5). Tasas de incidencia para infección anal: VPH alto-riesgo=7.8/1000 persona-meses (IC95%:6.0-10.1), VPH 16=1.8/1000 persona-meses (95%IC:1.1-2.9), tipos en vacu na tetravalente=3.4/1000 persona-meses y tipos en vacuna nonavalente=5.5/1000 persona-meses. Conclusiones. Implementación de programas de vacunación universal (incluyendo hombres) contra VPH es una prioridad en salud pública.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Fuchs W, Wieland U, Skaletz-Rorowski A, Brockmeyer NH, Swoboda J, Kreuter A, et al. The male ScreenING Study: prevalence of HPV-related genital and anal lesions in an urban cohort of HIV-positive men in Germany. J Eur Acad Dermatol Venereol. 2016;30(6):995-1001. https://doi. org/10.1111/jdv.13539

  2. Pamnani SJ, Nyitray AG, Abrahamsen M, Rollison DE, Villa LL, Lazcano- Ponce E, et al. Sequential acquisition of anal human papillomavirus (HPV) infection following genital infection among men who have sex with women: The HPV infection in men (HIM) Study. J Infect Dis. 2016;214(8):1180-7. https://doi.org/10.1093/infdis/jiw334

  3. Nyitray AG, Carvalho Da Silva RJ, Chang M, Baggio ML, Ingles DJ, Abrahamsen M, et al. Incidence, duration, persistence, and factors associated with high-risk anal human papillomavirus persistence among HIV-negative men who have sex with men: A multinational study. Clin Infect Dis. 2016;62(11):1367-74. https://doi.org/10.1093/cid/ciw140

  4. Nyitray AG, da Silva RJ, Baggio ML, Lu B, Smith D, Abrahamsen M, et al. The prevalence of genital HPV and factors associated with oncogenic HPV among men having sex with men and men having sex with women and men: the HIM study. Sex Transm Dis. 2011;38(10):932-40. https://doi. org/10.1097/OLQ.0b013e31822154f9

  5. Loverro G, Di Naro E, Caringella AM, De Robertis AL, Loconsole D, Chironna M. Prevalence of human papillomavirus infection in a clinic sample of transsexuals in Italy. Sex Transm Infect. 2016;92(1):67-9. https:// doi.org/10.1136/sextrans-2014-051987

  6. Torres-Ibarra L, Conde-Glez CJ, Salmerón J, Palefsky J, Hernández-Nevares P, Sánchez-Alemán MA, et al. Risk factors for anal HPV-16/18 infection in Mexican HIV-infected men who have sex with men. Prev Med (Baltim). 2014;69:157-64. https://doi.org/10.1016/j.ypmed.2014.09.011

  7. Bernat-García J, Morales Suárez-Varela M, Vilata-Corell JJ, Marquina-Vila A. Detection of human papillomavirus in nonmelanoma skin cancer lesions and healthy perilesional skin in kidney transplant recipients and immunocompetent patients. Actas Dermosifiliogr. 2014;105(3):286-94. https://doi. org/10.1016/j.ad.2013.10.011

  8. Morales R, Parada R, Giuliano AR, Cruz A, Castellsagué X, Salmeroń J, et al. HPV in female partners increases risk of incident HPV infection acquisition in heterosexual men in rural central Mexico. Cancer Epidemiol Biomarkers Prev. 2012;21(11):1956-65. https://doi.org/10.1158/1055-9965. EPI-12-0470

  9. Sendagorta E, Herranz P, Guadalajara H, Bernardino JI, Viguer JM, Beato MJ, et al. Prevalence of abnormal anal cytology and high-grade squamous intraepithelial lesions among a cohort of HIV-infected men who have sex with men. Dis Colon Rectum. 2014;57(4):475-81. https://doi.org/10.1097/ DCR.0000000000000095

  10. Müller EE, Rebe K, Chirwa TF, Struthers H, McIntyre J, Lewis DA. The prevalence of human papillomavirus infections and associated risk factors in men-who-have-sex-with-men in Cape Town, South Africa. BMC Infect Dis. 2016;16(1):440. https://doi.org/10.1186/s12879-016-1706-9

  11. Viens LJ, Henley SJ, Watson M, Markowitz LE, Thomas CC, Thompson TD, et al. Human Papillomavirus-Associated Cancers-United States, 2008- 2012. MMWR Morb Mortal Wkly Rep. 2016;65(26):661-6. https://doi. org/10.15585/mmwr.mm6526a1

  12. Kreuter A, Siorokos C, Oellig F, Silling S, Pfister H, Wieland U. High-grade dysplasia in anogenital warts of HIV-positive men. JAMA Dermatol. 2016;152(11):1225-30. https://doi.org/10.1001/jamadermatol. 2016.2503

  13. Reynoso-Noverón N, Meneses-García A, Erazo-Valle A, Escudero-de los Ríos P, Kuri-Morales PA, Mohar-Betancourt A. Challenges in the development and implementation of the National Comprehensive Cancer Control Program in Mexico. Salud Publica Mex. 2016;58:325-333. https:// doi.org/10.21149/spm.v58i2.7804

  14. Brotherton JML, Batchelor MR, Bradley MO, Brown SA, Duncombe SM, Meijer D, et al. Interium estimates of male human papillomavirus vaccination coverage in the school-based program in Australia. Commun Dis Intell Q Rep. 2015;39(2):E197-200.

  15. Nanagas VC, Stolfi A, Nanagas MT, Eberhart GM, Alter SJ. Adolescent Male Human Papillomavirus Vaccination. Glob Pediatr Health. 2016;3:2333794X16642373.

  16. Camacho-Gonzalez AF, Chernoff MC, Williams PL, Chahroudi A, Oleske JM, Traite S, et al. Sexually transmitted infections in youth with controlled and uncontrolled human immunodeficiency virus infection. J Pediatric Infect Dis Soc. 2017;6(3):e22-e29. https://doi.org/10.1093/ipids/piw039

  17. Giuliano AR, Lee J-H, Fulp W, Villa LL, Lazcano E, Papenfuss MR, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet. 2011;377(9769):932-40.

  18. Giuliano AR, Lazcano-Ponce E, Villa LL, Flores R, Salmeron J, Lee JH, et al. The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev. 2008;17(8):2036-43.

  19. Ishibashi MA, Antunes JA, Aoki MFC, Terreri RB, Brito E, Silva RC, et al. Human Papillomavirus infection in men residing in Brazil, Mexico, and the USA. Salud Publica Mex. 2008;50(5):408-18.

  20. Nyitray AG, Carvalho da Silva RJ, Baggio ML, Lu B, Smith D, Abrahamsen M, et al. Age-specific prevalence of and risk factors for anal human papillomavirus (HPV) among men who have sex with women and men who have sex with men: the HPV in men (HIM) study. J Infect Dis. 2011;203(1):49-57. https://doi.org/10.1093/infdis/jiq021

  21. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlée F, Hildesheim A, et al. Improved amplification of genital human papillomaviruses. J Clin- Microbiol. 2000; 38:357-61.

  22. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 human papilloma virus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol. 1998;36:3020-7.

  23. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. WHO International Agency for Research on Cancer. Carcinogenicity of human papilloma viruses. Lancet Oncol. 2005;6(4):204. https://doi.org/10.1016/ S1470-2045(05)70086-3

  24. Tejada RA, Vargas KG, Benites-Zapata V, Mezones-Holguín E, Bolaños- Díaz R, Hernández AV. Human papillomavirus vaccine efficacy in the prevention of anogenital warts: systematic review and meta-analysis. Salud Publica Mex. 2017;59:84-94. https://doi.org/10.21149/7824

  25. Svare EI, Kjaer SK, Worm AM, Osterlind A, Meijer CJ, van den Brule AJ. Risk factors for genital HPV DNA in men resemble those found in women: a study of male attendees at a Danish STD clinic. Sex Transm Infect. 2002;78(3):215-8. https://doi.org/10.1136/sti.78.3.215

  26. Partridge JM, Hughes JP, Feng Q, Winer RL, Weaver BA, Xi LF, et al. Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis. 2007;196(8):1128-36. https:// doi.org/10.1086/521192

  27. Jin F, Prestage GP, Imrie J, Kippax SC, Donovan B, Templeton DJ, et al. Anal sexually transmitted infections and risk of HIV infection in homosexual men. J Acquir Immune Defic Syndr. 2010;53(1):144-9. https://doi. org/10.1097/QAI.0b013e3181b48f33

  28. Garland SM, Kjaer SK, Muñoz N, Block SL, Brown DR, DiNubile MJ, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: A systematic review of 10 years of real-world experience. Clin Infect Dis. 2016;63(4):519-27. https://doi.org/10.1093/cid/ciw354

  29. Drolet M, Bénard É, Boily MC, Ali H, Baandrup L, Bauer H, et al. Population- level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565-80. https://doi.org/10.1016/S1473-3099(14)71073-4

  30. Bray F, Piñeros M. Cancer patterns, trends and projections in Latin America and the Caribbean: a global context. Salud Publica Mex. 2016;58(2):104-17. https://doi.org/10.21149/spm.v58i2.7779

  31. Salmerón J, Torres-Ibarra L, Bosch FX, Cuzick J, Lörincz A, Wheeler CM, et al. HPV vaccination impact on a cervical cancer screening program: methods of the FASTER-Tlalpan Study in Mexico. Salud Publica Mex. 2016;58(2):211-9. https://doi.org/10.21149/spm.v58i2.7790




2020     |     www.medigraphic.com